**SUPPLEMENTARY MATERIAL**

Methods

Study data included asthma severity (following GINA guidelines) (1) and control (assessed using the Asthma Control Test) (2). Adherence to treatment was measured with the Test of Adherence to Inhalers (TAI) (3). Table 1 specifies the patient's controller therapy. Table 2 specifies the non-significant comorbidities between both groups. The 2012 Global Lung Initiative reference equations (4) were used to generate predicted values and Z-scores for FEV1, FVC and FEV1/FVC ratio.

**Table 1. Patient's controller therapy**

| | **ACT ≥ 20**<br>**n = 94** | **ACT < 20**<br>**n = 19** | **p** |
|---|---|---|---|
| **Antihistamines, n (%)** | 43 (46) | 9 (47) | 0.897 |
| **Oral corticosteroids**<br>**n (%)**<br>**doses, mg / day** | <br>16 (17)<br>5 (2.5 – 25) | <br>4 (20)<br>5 (5 – 15) | 0.586 |
| **LABA, n (%)** | 87 (92) | 19 (100) | 0.219 |
| **LAMA, n (%)** | 57 (61) | 16 (84) | **0.05** |
| **Montelukast, n (%)** | 45 (48) | 17 (89) | **0.001** |
| **Theophylline, n (%)** | 2 (2) | 0 (0) | 0.521 |
| **Azithromycin, n (%)** | 9 (9) | 7 (37) | **0.002** |

LABA - Long-acting ß2- agonists; LAMA - Long-acting muscarinic antagonists.





doi: 10.18176/jiaci.0941

**Table 2. Control and exacerbations of patients with different biological treatments**

| | Omalizumab n = 62 | Benralizumab n = 27 | Mepolizumab n = 21 | Reslizumab n = 3 | p |
|---|---|---|---|---|---|
| **ACT, median (range)** | 23 (11 – 25) | 23 (10 – 25) | 25 (16 – 25) | 23 (22 – 25) | 0.529 |
| **ACT < 20, n (%)** | 11 (18) | 4 (15) | 2 (9) | 0 (0) | |
| **Severe exacerbations, n (%)** | 18 (29) | 4 (15) | 4 (19) | 0 (0) | 0.948 |
| **Hospital admissions last 18 months, n (%)** | 2 (3) | 0 (0) | 1 (5) | 0 (0) | 0.417 |

**Table 3. Comorbidities**

| | n = 113 | ACT ≥ 20 n = 94 | ACT < 20 n = 19 | p |
|---|---|---|---|---|
| **Atopy, n (%)** | 81 (72) | 66 (79) | 15 (79) | 0.441 |
| **Gastroesophageal reflux, n (%)** | 21 (19) | 15 (16) | 6 (31) | 0.110 |
| **Heart disease, n (%)** | 6 (5) | 5 (5) | 1 (5) | 0.992 |
| **Arterial hypertension, n (%)** | 27 (24) | 20 (21) | 7 (37) | 0.147 |
| **Dyslipidemia, n (%)** | 27 (24) | 23 (24) | 4 (21) | 0.750 |
| **Diabetes, n (%)** | 8 (7) | 7 (7) | 1 (5) | 0.735 |
| **Neurological disease, n (%)** | 13 (12) | 12 (13) | 1 (5) | 0.350 |
| **Psychiatric disease, n (%)** | 22 (19) | 17 (18) | 5 (26) | 0.409 |
| **Digestive disease, n (%)** | 13 (12) | 12 (13) | 1 (5) | 0.350 |





doi: 10.18176/jiaci.0941

**References**


1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019. www.ginasthma.org. Accessed September 3, 2020.
2. Vega JM, Badia X, Badiola C, et al. Validation of the Spanish version of the asthma control test (ACT). J Asthma. 2007;44:867-872.
3. Plaza V, López-Viña A, Cosio BG. Test of adherence to inhalers. Arch Bronconeumol. 2017;53(7):360-361.
4. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012; 40(6):1324–43.






doi: 10.18176/jiaci.0941